An observational study in Atrial Fibrillation and Atrial Cardiomyopathy, sponsored by Atrial Fibrillation Network. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Atrial Fibrillation Network · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Atrial Fibrillation by Atrial Fibrillation Network — 2 open to participants now, 2 under way, none of them phase 3. Atrial Fibrillation · Atrial Fibrillation Network.
Among the 13 studies in Atrial Fibrillation by Atrial Fibrillation Network, this one is the only one that started in 2023, is one of 3 observational ones, and was the 11th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →2 of the 13 studies in Atrial Fibrillation by Atrial Fibrillation Network are open now, in 7 countries. Recruiting first, the newest first:
Atrial Fibrillation Network · Sites in Australia, Canada, Germany and 4 more countries
Ages 18+
Atrial Fibrillation Network · Sites in Germany
Ages 18+
By country, each count listing its studies:
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 515 is above the median of 300 across 1,405 observational studies indexed under Atrial Fibrillation.
Median enrollment 718 across the 10 interventional studies, 515 across the 3 observational. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
Atrial Fibrillation Network is the lead sponsor of 14 studies on the registry; 2 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Atrial Fibrillation by Atrial Fibrillation Network, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The MAESTRIA study is an international, multi-centre, non-interventional, observational registry. The main goal is to enrol a representative group of European patients diagnosed with Atrial Fibrillation (AF) to analyse clinical and relevant parameters (digitalised ECG, echocardiograms, cardiac CTs, MRIs and blood biomarkers) that could be used during clinical practise for the diagnosis of atrial cardiomyopathy. The AF patients will be distributed in 3 groups according to the different manifestation of AF: paroxysmal, persistent and permanent AF.
Atrial fibrillation (AF) and stroke are major health care problems in Europe. They are most often the clinical expression of atrial cardiomyopathy, which is under-recognised due to the lack of specific diagnostic tools. Multidisciplinary research and stratified approaches are urgently needed to prevent, diagnose, and treat AF and stroke and preempt the AF-related threat to healthy ageing in Europe.
MAESTRIA is a European consortium of 18 clinicians, scientists and pharma industry partners who are at the forefront of research and medical care of AF and stroke patients funded by the EU Horizon 2020 programme (grant number 965286). The Atrial Fibrillation Network (AFNET) is one of the 18 partner institutions in this European consortium.
MAESTRIA will create multi-parametric digital tools based on a new generation of biomarkers that integrate artificial intelligence (AI) processing and big data from cutting edge imaging, electrocardiography and omics technologies. It will develop novel biomarkers, diagnostic tools and personalized therapies for atrial cardiomyopathy.
The MAESTRIA-AFNET 10 Study is an integral part of the MAESTRIA project. The study will collect relevant clinical parameters for AF from patients, this includes ECGs, cardiac CTs, MRIs and echocardiograms. Dedicated core labs will collect and homogenize the clinical data.
For atrial arrhythmias (AA) and vascular stiffness index (VSI) recording, patients will be provided with a measuring bracelet for continuous monitoring of heart rhythm with a photoplethysmographic (PPG) sensor coupled with a smartphone app and the Preventicus Heartbeats® analytic service (Class IIa, CE marked), approved as consumer device. Preventicus is ISO 13485 certified.
European prospective cohort of patients with diagnosed AF.
Patients are distributed in 3 groups according to the different clinical manifestation of AF:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
215 patients
216 patients
84 patients
Physical examination
Weight (Kilograms-Kg) Height (centimeters-cm) Weight and height will be combined to calculate BMI in Kg/m\^2
Time frame: 12 months
Clinically relevant changes in CT/MRI
only if clinically indicated
Time frame: 12 months
Atrial Arrythmias (AA) burden and vascular stiffness (measured by a measuring bracelet)
AA burden and vascular stiffness measured by the measuring bracelet
Time frame: 12 months
Cognitive function test (MoCA)
evaluation of cognitive function (includes different tasks: visual/executive; naming; memory; attention; language; abstraction; delayed recall; orientation). Total score will be calculated and collected.
Time frame: Baseline and Follow up at 12 months
EQ-5D-5L Quality of Life questionnaire
quality of life assessment (includes questions about mobility, self care, usual activities, pain/discomfort and anxiety/depression). The health state code will be collected (calculated as concatenation of 5 scores). Health score from vertical visual analogue scale (0-100) will be collected.
Time frame: Baseline and Follow up at 12 months
Ischaemic events (systemic, myocardial and cerebral)
ischaemic events
Time frame: 12 months
Echo analysis (TEE_transesophageal echocardiography): LAA smoke available
collected as Yes/No
Time frame: 12 months
Echo analysis (TEE_transesophageal echocardiography): Flow velocity in LAA
measured in cm/sec
Time frame: 12 months
Echo analysis (TEE_transesophageal echocardiography): Antrum diameter
measured in mm
Time frame: 12 months
Echo analysis (TTE_transthoracic echocardiography): LVEF
Measured in %; Biplane Simpson Method
Time frame: 12 months
Echo analysis (TTE_transthoracic echocardiography): LA diameter
measured in mm LA volume (mL) Septum thickness (mm) Degree of mitral valve insufficiency (Grade I/trivial; Grade II/moderate; Grade III/moderate to severe; Grade IV/severe; None). Degree of tricuspid valve insufficiency (Grade I/trivial; Grade II/moderate; Grade III/moderate to severe; Grade IV/severe; None).
Time frame: 12 months
Echo analysis (TTE_transthoracic echocardiography): LA volume
measured in mL
Time frame: 12 months
Echo analysis (TTE_transthoracic echocardiography): Septum thickness
measured in mm Degree of mitral valve insufficiency (Grade I/trivial; Grade II/moderate; Grade III/moderate to severe; Grade IV/severe; None). Degree of tricuspid valve insufficiency (Grade I/trivial; Grade II/moderate; Grade III/moderate to severe; Grade IV/severe; None).
Time frame: 12 months
Echo analysis (TTE_transthoracic echocardiography): Degree of mitral valve insufficiency
Grade I/trivial; Grade II/moderate; Grade III/moderate to severe; Grade IV/severe; None
Time frame: 12 months
Echo analysis (TTE_transthoracic echocardiography): Degree of tricuspid valve insufficiency
Grade I/trivial; Grade II/moderate; Grade III/moderate to severe; Grade IV/severe; None
Time frame: 12 months
ECG analysis
Electrocardiogram analysis (paper and digital, if available). \- 12-lead body surface ECG will be collected. Variables to be collected in the eCRF: Heart Rhythm (Sinus rhythm; Atrial Fibrillation; Continuous pacing; Pacing and AF; other (specify as free text). Heart rate (beats/min) Heart axis (degrees) QRS interval (msec) PR interval (msec) P-wave duration (msec) QT-duration (msec) QTcF (msec) Other relevant ECG findings (to add as free text).
Time frame: 12 months
MRI analysis: LAEF
Left atrial ejection fractio measured in %
Time frame: 12 months
MRI analysis: LAVi
LAVi left atrial volume index measured in ml/m\^2
Time frame: 12 months
MRI analysis: LALRS
LALRS left atrial longitudinal reservoir strain measured in %
Time frame: 12 months
MRI analysis: LALBS
LALBS left atrial longitudinal booster strain measured in %
Time frame: 12 months
CT scan analysis
The cardiac CTs will be sent to the specialised core lab for analysis. The analysis will include: Atriomic risk of stroke (5 year event risk) Yes/No
Time frame: 12 months
CT scan: Atriomic risk for AF
5 year event risk: Yes/No
Time frame: 12 months
CT scan: Epicardial Adipose tissue volume
measured in cm\^3
Time frame: 12 months
CT scan: Epicardial adipose tissue mean attenuation
measured in HU
Time frame: 12 months
CT scan: Left atrium volume
measured in cm\^3
Time frame: 12 months
Ran from Mar 2023 to primary completion in Jul 2026, 40 months.
Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's 40 months is below that.
Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Aug 2024 → Jul 2026 and completion Aug 2025 → Aug 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Atrial Fibrillation Network